Hospital Universitario Puerta del Mar -ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2022

  1. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

    International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392

2020

  1. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia

    European Journal of Haematology, Vol. 104, Núm. 3, pp. 259-270

2017

  1. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970

2015

  1. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43

2014

  1. Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?

    American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211